{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:32:04Z","timestamp":1794641524697,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01270-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:44:03Z","timestamp":1743792243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1270_CR2","doi-asserted-by":"publisher","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27625. Online ahead of print.","DOI":"10.1002\/ajh.27625"},{"key":"1270_CR3","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","volume":"13","author":"M Andreeff","year":"1999","unstructured":"Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881\u201392.","journal-title":"Leukemia"},{"key":"1270_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"1270_CR5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","volume":"56","author":"JM Bogenberger","year":"2015","unstructured":"Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56:226\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1270_CR6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"1270_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"1270_CR8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"1270_CR9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"1270_CR10","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022;107:2501\u20135.","journal-title":"Haematologica"},{"key":"1270_CR11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1270_CR12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol. 2025;100:260\u201371.","journal-title":"Am J Hematol"},{"key":"1270_CR13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020;38:872\u201390.e6.","journal-title":"Cancer Cell"},{"key":"1270_CR14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"1270_CR15","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144:2211\u201322.","journal-title":"Blood"},{"key":"1270_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1270_CR17","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, et al. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022;97:E416\u2013e9.","journal-title":"Am J Hematol"},{"key":"1270_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.27515","volume":"100","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Ill\u00e9s \u00c1, et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2025;100:185\u20138.","journal-title":"Am J Hematol"},{"key":"1270_CR19","unstructured":"Willekens C, B A, Chraibi, S, Bataller, A, Decroocq, J, Arani, N et al. Reduced Venetoclax Exposure to 7 days vs Standard Exposure With Hypomethylating Agents In Newly Diagnosed AML patients. Blood Cancer J. (in Press). 2025."},{"key":"1270_CR20","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28\u2009days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol. 2024;99:E63\u20136.","journal-title":"Am J Hematol"},{"key":"1270_CR21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541\u20136.","journal-title":"Ann Hematol"},{"key":"1270_CR22","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2024-200013","volume":"144","author":"M Kanaya","year":"2024","unstructured":"Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, et al. Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net. Blood. 2024;144:6063.","journal-title":"Blood"},{"key":"1270_CR23","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2024-209246","volume":"144","author":"AA Ginosyan","year":"2024","unstructured":"Ginosyan AA, Ashouri K, Humayun L, Ford L, Baya M, Hong H-J, et al. Optimizing venetoclax duration in combination with hypomethylating agents for newly diagnosed AML: impact on treatment response and survival outcomes. Blood. 2024;144:2892.","journal-title":"Blood"},{"key":"1270_CR24","volume":"29","author":"J Cui","year":"2024","unstructured":"Cui J, Chen X, Li C, Yan Q, Yuan G. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Hematology. 2024;29:2293512.","journal-title":"Hematology"},{"key":"1270_CR25","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2024025834","volume":"144","author":"M Goldfinger","year":"2024","unstructured":"Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, et al. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024;144:2360\u20133.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01270-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:44:39Z","timestamp":1743792279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01270-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01270-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG has served on the Advisory Board for Agio and DISC Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}